Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 170,441 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock in a transaction on Friday, June 12th. The shares were sold at an average price of $0.40, for a total value of $68,176.40. Following the sale, the insider directly owned 349,907 shares of the company’s stock, valued at approximately $139,962.80. This trade represents a 32.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $55,361.25.
• On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.39, for a total value of $50,220.30.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 7.4%

HOWL opened at $0.36 on Wednesday. The firm has a market cap of $17.50 million, a price-to-earnings ratio of -0.29 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $2.38. The stock has a fifty day moving average price of $0.63 and a 200-day moving average price of $0.70.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HOWL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Werewolf Therapeutics has an average rating of “Hold” and a consensus target price of $3.75.

Institutional Trading of Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the company. Regal Investment Advisors LLC grew its stake in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. grew its stake in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the 2nd quarter valued at about $48,000. AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC grew its stake in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.